Caplacizumab  (Synonyms: ALX-0681; ALX-0081)

Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP)^[1][2][3][4].

VH-VH

Humanized

Caplacizumab inhibits the binding of VWF with platelet glycoprotein (GP) Ibα in blood specimens^[2].
Caplacizumab (0.8 μg/mL) can completely inhibit platelet adhesion to the collagen surface at high shear rates (>1500 s^-1)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Caplacizumab (2.5 mg/kg, s.c., daily, from day 1 to day 5 for preventive group) completely prevents the rapid onset of severe thrombocytopenia and schistocytic hemolytic anemia in a baboon model of acquired thrombotic thrombocytopenic purpura, and promotes the recovery of platelet counts after induction of TTP^[3].
Caplacizumab (at plasma levels between 0.3-0.5 μg/mL, i.v. bolus) shows a strong antithrombotic effect in a modified Folts model in baboons^[4].
Caplacizumab (5 mg/kg total dose with intravenous and subcutaneous injection; intravenous injection first and subcutaneous injections follow) prevents middle cerebral artery thrombosis in a guinea pig model of middle cerebral artery thrombosis, and reduces brain damage without inducing hemorrhage^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

27876.19

915810-67-2

Liquid

Colorless to light yellow

[Caplacizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  VH-VH

• [1]. Maëlle le Besnerais, et al. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134.  [Content Brief]

  [2]. Nakayama M, et al. Effects of caplacizumab, a specific inhibitor of the A1 domain of von Willebrand factor binding with platelet membrane glycoprotein (GP) Ibα, on the length of platelet pseudopods supporting platelet adhesions on immobilized von Willebrand factor under blood flow condition. Journal of Biorheology, 2022, 36(2): 68-75.

  [3]. Callewaert F, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012 Oct 25;120(17):3603-10.  [Content Brief]

  [4]. Ulrichts H, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011 Jul 21;118(3):757-65.  [Content Brief]

  [5]. Momi S, et al. Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood. 2013 Jun 20;121(25):5088-97.  [Content Brief]